Morcellator Cancer Lawsuits
Surgical rotating blade devices are power morcellators used to grind into tiny fragments uterine fibroids.
Then, the fragments from the abdomen can be suctioned out via an incision that is small.
The design, unfortunately, of the morcellator approved by the FDA previously usually leaves behind small tissue fragments, which may easily spread cancer.
Many physicians, in addition, have become negligent in their involvement by failing to determine prior to using the device if the uterine fibroids can spread cancer.Failure to Warn Patients About Morcellator Dangers
Morcellator cancer lawsuits result in attorneys hired by women following a procedure via morcellation have developed cancer.
The U.S. Food & Drug Administration has issued a warning to physicians, medical device manufacturers, and women that morcellators are potentially spreading cancer that was undetected previously.
This warning issued leads to many investigations of those with leiomyosarcoma diagnosis, who had had removal of uterine fibroids by a physician with the use of a power morcellator.
Hundreds of thousands of females, since the 1990s, have each year had hysterectomies and removal of fibroid tumors.
Many hysterectomies, in fact, are administered by way of treating uterine fibroids.
The US Food & Drug Administration believes that the rare deadly cancer of leiomyosarcoma may be spread within the abdominal cavity of a woman due to removal of fibroid tumor, or hysterectomies from power morcellator procedures.
Morcellator cancer lawsuits can result when women with leiomyosarcoma and various cancer forms after a morcellator procedure hire lawyers to help them receive compensation, which are entitled for non-economic and medical care expenses.
Attorneys are available also to discuss any status of power morcellator lawsuits.
Many physicians and manufacturers of medical devices neglect to warn patients of the increased level of risk that involves morcellators used to administer hysterectomies and fibroid removal.
Across the United States, many medical centers have ceased the use of the morcellator long before the warning from the FDA.
Research has disclosed information related to the involved risks in power uterine morcellation minimally invasive, and the key risks which may be arise for any woman sustaining uterine cancer undetected.
Fibroid tumors and cancer cells seem to spread easily throughout the abdominal and pelvis areas when the uterus is extracted via a power morcellator.
This can place the health of women at critical risk when they undergo this procedure.
Various companies become embroiled in morcellator cancer lawsuits.
The companies that have marketed morcellators since the late 1990s include the following: Olympus, Johnson & Johnson, Smith & Nephew, Blue Endo, FemRX, Nouvag, Richard Wolf, Hologic, LiNA Medical, Lumenis Inc., and Interlace Medical.
For use by the FDA in 1995, since the devices of power morcellation were initially approved, less than 1 percent is the percentage of uterine sarcoma involving the total of women with removal of uterine fibroids.
This is due to physicians not being able to find easy and reliable methods to test for this type of cancer.